Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1141-1150 of 2859 for cancer

Edit search filters
  1. Testing The Addition Of Ixazomib To Lenalidomide In Patients With Evidence Of Residual Multiple Myeloma, OPTIMUM Trial

    La Crosse, WI, Rochester, MN

  2. A Study Comparing Temozolomide and Selumetinib for Treating Patients with Metastatic Melanoma of the Eye

    Rochester, MN

  3. A Study Of Lower Radiotherapy Dose To Treat Children With CNS Germinoma

    Rochester, MN

  4. Cabozantinib-S-Malate In Treating Younger Patients With Recurrent, Refractory, Or Newly Diagnosed Sarcomas, Wilms Tumor, Or Other Rare Tumors

    Rochester, MN

  5. A Study of Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia, or Refractory or Relapsed Acute Myelogenous Leukemia

    Rochester, MN

  6. A Study of Everolimus with or without Bevacizumab for Treating Patients with Advanced Kidney Cancer that Progressed after First-Line Therapy

  7. A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  8. A Study Of Ramucirumab (LY3009806) In Children And Young Adults With Synovial Sarcoma

    Jacksonville, FL

  9. Dendritic Cell Therapy After Cryosurgery In Combination With Pembrolizumab In Treating Patients With Stage III-IV Melanoma That Cannot Be Remove By Surgery

    Rochester, MN

  10. Prospective Use of Real-time MRI

    Rochester, MN

.

Mayo Clinic Footer